Kairos Pharma Ltd. (NYSE American: KAPA) announced that its CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles. The presentation will provide an update on the company’s clinical program and partnering activities, offering investors and industry leaders insight into the progress of its lead candidate, ENV-105.
ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard cancer therapies. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard treatments across multiple cancer types. The molecule is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The LD Micro Invitational is a prominent investor conference that brings together emerging growth companies and the investment community. For Kairos Pharma, this presentation represents an opportunity to showcase its innovative approach to oncology therapeutics, which leverages structural biology to overcome drug resistance and immune suppression in cancer. The company’s focus on CD105 as a target could have broad implications for patients with hard-to-treat cancers, particularly those who have developed resistance to current therapies.
For leaders in the business and technology sectors, the advancement of ENV-105 underscores the growing intersection of biotechnology and artificial intelligence in drug discovery. While Kairos Pharma’s approach relies on structural biology, the broader trend of using computational methods to identify novel targets like CD105 is reshaping the pharmaceutical landscape. Successful clinical outcomes could lead to new treatment paradigms and significant market opportunities, as drug resistance remains a major challenge in oncology.
The presentation at the LD Micro Invitational may also signal potential partnering or licensing discussions, which could accelerate the development and commercialization of ENV-105. Investors and industry watchers will be keen to hear Dr. Yu’s update on clinical trial progress and any strategic initiatives. For more information, the full press release is available at https://ibn.fm/g3aQY, and the latest news and updates relating to KAPA can be found in the company’s newsroom at https://ibn.fm/KAPA.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to address drug resistance and immune suppression. As the company progresses its clinical programs, the implications for patients and the oncology market could be substantial.
